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ABSTRACT
Introduction Children with primary immunodeficiency 
disorders (PID) are more susceptible to developing viral 
infections and are at a substantially increased risk of 
developing paralytic poliomyelitis. Such children, if given oral 
polio vaccines tend to excrete poliovirus chronically that may 
lead to the propagation of highly divergent vaccine- derived 
poliovirus (VDPV). Consequently, they may act as a reservoir 
for the community by introducing an altered virus potentially 
imposing a risk to global polio eradication. However, the risks 
of chronic and prolonged excretion are not well characterised 
in the study context. This study seeks to establish a pilot 
surveillance system for successful identification and 
monitoring of VDPV excretion among children with PID. It will 
assess whether the Jeffrey Modell warning signs of PID can 
be used as an appropriate screening tool for PID in Pakistan.
Methods and analysis In this pilot surveillance, 
recruitment of PID cases is currently done at participating 
hospitals in Pakistan. Potential children are screened 
and tested against the Jeffrey Modell Foundation (JMF) 
warning signs for immunodeficiency and their stool is 
collected to test for poliovirus excretion. Cases excreting 
poliovirus are followed until the two consecutive negative 
stool samples are obtained over a period of 6 months. 
The data will be analysed to calculate hospital- based 
proportions of total Immunodeficiency- related vaccine- 
derived poliovirus (iVDPV) cases over a 2- year period and 
to determine the sensitivity and specificity of the JMF 
signs.
Ethics and dissemination This protocol was 
reviewed and approved by the WHO (WHO 
Reference-2018/811124-0), Aga Khan University (AKU 
ERC-2018-0380-1029) and National Bioethics Committee 
(Ref No. 4-87 NBC-308- Y2). The results will be published 
in an open access peer- reviewed scientific journal and 
presented to the iVDPV Working Group members, policy- 
makers, paediatric consultants and fellow researchers with 
the same domain interest. It may be presented in scientific 
conferences and seminars in the form of oral or poster 
presentations.
INTRODUCTION
Polio is a highly infectious viral disease which 
invades the nervous system of a child and 
may cause irreversible paralysis.1 The use 
of the live oral poliovirus vaccine (OPV) in 
routine and supplementary immunisation 
activities has significantly reduced the inci-
dence of paralytic poliomyelitis and transmis-
sion of wild polioviruses around the globe. 
This success can be attributed to the ability of 
this vaccine to induce mucosal immunity as 
well as serum neutralising antibodies protec-
tive against paralytic poliomyelitis.2 However, 
individuals with primary immunodeficiency 
disorders (PID) exposed to OPV through 
vaccination or household contacts are not 
only at increased risk of vaccine- associated 
paralytic poliomyelitis but may also have 
prolonged excretion of Sabin vaccine- derived 
polioviruses (VDPVs).3 Sabin polioviruses are 
known to have increased transmissibility and 
neurovirulence following prolonged intes-
tinal replication. Such individuals could theo-
retically transmit the virus to contacts and the 
general population following the interrup-
tion of wild poliovirus transmission.4 These 
polioviruses are called immunodeficiency- 
related vaccine- derived poliovirus (iVDPVs), 
Strengths and limitations of this study
 ► Primary immunodeficiency disorders (PID) patients 
are screened for excretion of poliovirus for the first 
time in Pakistan.
 ► Jeffrey Modell warning signs for PID are used to-
gether with immunological diagnostic testing for 
PID.
 ► Poliovirus excretors are followed up in monthly in-
tervals until two consecutive samples are negative.
 ► Proportions and types of poliovirus excretors among 
PID patients are analysed monthly.
 ► While attempts were made to cover entire Pakistan, 
the screening may miss PID cases in more remote 
areas.
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which indicates that these viruses have replicated and 
evolved in immunocompromised individuals. Previous 
studies in Sri Lanka, Egypt, Bangladesh and elsewhere 
demonstrated that it is essential to identify PID persons 
excreting polioviruses.1 5 6
Poliovirus excretion into the environment negates 
global poliovirus eradication efforts. PID individuals 
infected with poliovirus are at risk of developing paral-
ysis. Antiviral therapy will be offered to those identified 
immunodeficient children who are excreting polioviruses 
to prevent the spread of these polioviruses.
Aim
Identification and diagnosis of PID is complex and requires 
specialist interventions. The Jeffrey Modell Foundation 
(JMF) has developed 10 warning signs for the screening of 
suspected primary immunodeficiency patients.7 Although 
this screening tool has been used in various countries, its 
sensitivity and specificity in low- resource countries such as 
Pakistan have not been assessed. The primary aim of this 
project is to develop a pilot surveillance system for the 
identification of primary immunodeficient children in 
sentinel sites of Pakistan which will provide the basis for 
the development of longer- term surveillance structure for 
the successful identification, genetic characterisation and 
monitoring of VDPV excretion. This will help in identi-
fying long- term poliovirus excretors among them, which 
will in return help in the prevention of future transmis-
sion and VDPV outbreaks.
Secondary aims will be to calculate the hospital- based 
proportion of iVDPV cases and to document the identi-
fied iVDPV cases in the WHO global registry list. Finally, 
it will help assess whether the Jeffrey Modell warning 




The surveillance of iVDPV is currently being under-
taken at participatory tertiary healthcare facilities around 
Pakistan. This pilot surveillance will help in structuring 
a sustainable, long- term surveillance for PID children 
in Pakistan. In the initial stage, mapping was executed 
to identify participatory hospitals and their consultant 
paediatricians. Master training workshops were then 
conducted for these paediatricians from the selected 
hospitals of each province of Pakistan who agreed to 
participate in iVDPV surveillance. The project was rolled 
out as follows:
 ► First 6 months: Aga Khan University (AKU) Hospital+-
three other major tertiary care hospitals in Karachi
 ► Months 7–24: AKU Hospital+major hospitals in Kara-
chi+tertiary hospitals located in the provinces of 
Sindh (Hyderabad), Punjab (Lahore, Multan, Islam-
abad), Balochistan (Quetta), Khyber Pakhtunkhwa 
and Gilgit- Baltistan.
Training of master trainers workshop
The master training workshops were conducted all over 
the country in collaboration with WHO, Pakistan. All 
tertiary care hospitals in each province with paediatri-
cians were approached. Across Pakistan, 49 tertiary care 
hospitals have been participating in iVDPV surveillance. 
The participatory rate from the province Sindh (n=7) 
and Balochistan (n=3) is 100%, followed by 72.5% (n=29) 
from the province Punjab. The participatory proportion 
from the province Khyber Pakhtunkhwa (n=10) is 38.5%, 
which is the lowest among the remaining provinces 
(figure 1). The purpose of the training workshop was to 
train the master trainers who in turn guided their depart-
mental doctors for screening and identification of PID 
children using the JMF warning signs.
The master training workshops were conducted by 
the principal investigator (PI) of this project who is a 
paediatric infectious diseases consultant at the Aga Khan 
University Hospital in collaboration with WHO experts in 
Polio Surveillance.
Coordination process
This study requires close collaboration and coordina-
tion among the stakeholders. The Aga Khan University 
Hospital (Pakistan) is the main coordination centre for 
the study. A research coordinator (RC) serves as a liaison 
between the participatory hospitals in each province 
and the WHO provincial team, which collects the stool 
samples of identified PID children. National Institute of 
Health, Islamabad virology lab processes the stool samples 
and identifies the type of poliovirus.
Data collection process
Children are identified by the paediatricians trained on 
Jeffrey Model Foundation warning signs and the diag-
nosis of primary immunodeficiency. Any child (up to 18 
years of age) fulfilling the criteria of two or more posi-
tive JMF signs, will be further assessed and tested for HIV. 
The children who test negative for HIV, either suspected 
or confirmed PIDs are considered potential iVDPV 
excreters and are enrolled in the study. Enrolled children 
will be further tested for complete blood count (CBC), 
flow cytometry and quantitative measurement of immu-
noglobulins (QIGs) level after consulting with the coor-
dination cell at the Aga Khan University. A consultant 
haematologist at the Aga Khan University will review the 
flow cytometry and immunoglobulins level reports. After 
enrolment, WHO provincial teams collect two consecu-
tive stool samples, which are examined for poliovirus at 
National Institute of Health (NIH) Islamabad- Pakistan 
using standard poliovirus detection methodology used in 
the Global Polio Laboratory Network. The second stool 
sample will be collected 24 hours after the first sample. 
Any child found to be positive will be followed up with 
monthly stool samples for 6 months or till two subsequent 
samples become negative. All iVDPVs detected will be 
documented in the WHO global registry list of known 
iVDPV cases.
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Follow-up with the iVDPV cases
The parents or guardians of iVDPV positive children 
are informed and followed up closely by Expanded 
Programme on Immunization (EPI) and Union Council 
teams along with WHO provincial teams. Children 
are followed up until two consecutive negative stool 
samples for a period of 6 months. However, if the child 
is still found to be an excretors at 6 months, they will be 
provided antiviral therapy for poliovirus excretion. This 
therapy would be provided to the affected child free of 
cost.
The children who test negative for VDPVs or Sabin- like 
virus, follow- up stool sample collection will be done after 
a year.
Process
In order to maximise the surveillance coverage of 
primary immune deficient children, hospital paedia-
tricians will be sufficiently sensitised to the necessary 
referral process.
Children with suspected PID screened using JMF 
warning signs will be enrolled and the following labo-
ratory investigations would be sent for confirmation 
(figure 2).
 ► CBC (absolute neutrophil and lymphocyte count).
 ► HIV.
 ► Flow cytometry (B and T cell markers).
 ► QIGs test.
Patient and public involvement
Considering the nature of the study, it was not possible 
to have a priori patient involvement. The country lead-
ership from WHO and National Emergency Operations 
Centre were consulted during the study designing to safe-
guard public interest and safety.




For HIV testing, 3–5 mL of whole blood will be collected 
in a gel tube and K2- EDTA tube. Gel tube will be used 
for serology whereas, EDTA tube would use for PCR. 
Samples will be transported to the laboratory at 2°C–8°C. 
Initial HIV screening will be performed by chemilumi-
nescent immunoassay using ADVIA Centaur HIV Ag/Ab 
Combo assay kit run on ADVIA Centaur XP/CP analyser. 
Positive cases will be further confirmed by immunochro-
matographic antibody detection on Bio- Rad Genius HIV 
1/2 assay. In case of indeterminate results or discrepant 
results between the above two methods final confirma-
tion will be made by HIV PCR on Xpert HIV-1 Qual Assay 
kit and GeneXpert Dx System.
Complete blood count
For CBC, 3–4 mL whole blood sample will be collected in 
tubes containing K2 EDTA as an anticoagulant. Samples 
Figure 1 Participatory tertiary care hospitals. KPK, Khyber Pakhtunkhwa.
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will be transported as soon as possible to the stat/main 
laboratory. The temperature of 18°C–25°C will be main-
tained if the expected delivery time is within 8 hours, 
whereas 2°C–8°C will be maintained if samples are deliv-
ered after 8 hours up to a maximum of 3 days. Samples 
will be run on the fully automated Sysmex XN series anal-
ysers (Sysmex Japan).
Immunoglobulins
For immunoglobulin measurement, 3–5 mL of whole 
blood will be collected in a plain tube or gel tube. Trans-
portation temperature of 18°C–25°C (for 8 hours) and 
2°C–8°C after 8 hours to 24 hours will be maintained. 
Serum IgA, IgG, IgM will be measured on ADVIA 1800 
Chemistry analyser (Siemens Healthcare Diagnostics, 
New York, USA).
Flow cytometry
For lymphocyte subset analysis, 3–4 mL of whole blood 
will be collected in tubes containing K2 EDTA or sodium 
heparin as an anticoagulant. All samples will be trans-
ported at 2°C–8°C within 24 hours. Lymphocyte subset 
analysis will be performed by flow cytometry using FC500 
MCL Flow Cytometer (Beckman Coulter, Miami, Florida, 
USA). Monoclonal antibodies against following antigens 
were used: T- lineage- associated antigens CD3, CD4 and 
CD8; B- lineage antigen CD19 and Natural Killer cell 
antigen CD56.
For CBC and immunoglobulin levels, three different 
levels of manufacturer- provided controls (low, normal 
and high) will be run with each batch as an internal 
quality control measure. Whereas, for lymphocyte subset 
analysis two levels (low and normal) commercial controls 
will be used. External proficiency is assured by simulta-
neously analysing samples from the College of American 
Pathologists two times per year for immunoglobulin levels 
and three times per year for both CBCs and lymphocyte 
subset analysis.
Following samples will be considered unsatisfactory for 
analysis: unlabeled or mislabeled samples, identification 
mismatch between specimen and requisition slip, haemo-
lysed or clotted samples, wrong collection tube, insuffi-
cient specimen quantity, excessive delay in specimen 
Figure 2 Flow diagram of the study process. AKU, Aga Khan University; CBC, complete blood count; ANC, Absolute 
Neutrophil Count; ALC, Absolute Lymphocyte Count; KPK, Khyber Pakhtunkhwa; NIH, National Institute of Health.
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transport or improperly transported (ie, not at required 
temperature).
Stool sample
Testing of stools for the isolation of poliovirus would be 
done according to the standardised protocol used at the 
Global Polio Laboratory Network.8 9 Two stool specimens 
from the enrolled suspected primary immunodeficient 
children will be collected in sufficient quantity (~10 g) 24 
hours apart. Then the samples will be shipped to WHO 
Regional Reference Laboratory for Polio Eradication 
Initiative, Virology Department, NIH- Islamabad, Pakistan 
within 48 hours maintaining reverse cold chain along 
with patient’s investigation questionnaire (also known 
as lab request form). The lab request form indicated 
all general information such as demographic details 
(patient’s name, age, sex and region), vaccination history 
and clinical information. Each sample will be provided a 
unique identity code (specimen number).
Samples will then be tested for isolation of specific 
serotypes. Stool sample processing will start with the 
tissue culture in which specimen will be grown. Second, 
the molecular method will be used for the isolation and 
identification of poliovirus serotypes. Third, two different 
assays of one- step real- time reverse transcriptase PCR 
(rRT- PCR) will be used for detection of polioviruses using 
the protocols and primers/probes corresponding to 5’ 
UTR and VP1 region. These assays will include Intra- typic 
differentiation rRT- PCR that is for the confirmation, sero-
type identification and characterisation for polioviruses. 
However, rRT- PCR will be used for VDPV screening for 
VDPVs screening. Testing will be done according to the 
WHO guidelines for the identification of poliovirus.
Data management and quality assurance
Data monitoring
Regular supervision for the identification of PID children 
at the selected surveillance hospital all over Pakistan will 
be done by the iVDPV Working Group members (WGM). 
From each hospital, there would be two designated 
members who would be comprehensively trained on 
Jeffrey Modell Signs and identification of primary immu-
nodeficiency by the study PI. These members will be 
held responsible for correct identification of JMF signs, 
reviewing the filled surveillance questionnaire to ensure 
that it is filled properly and training the postgraduate 
students, residents and fellows on fundamentals of the 
project. Moreover, the project PI and RC of the study will 
also review forms and make visits to monitor the surveil-
lance activity and to guide the iVDPV- WGM whenever 
required. This iVDPV- WGM will also update RC about the 
daily progress of the study via phone calls or by sending a 
medical history summary report of suspected PIDs on the 
WhatsApp group generated for this study.
Quality of data collection will be ensured by proper 
training of the iVDPV- WGM. Quality will also be ensured 
through supervision and reviewing of the data collected 
by the PI. Moreover, skype/zoom meetings will be 
arranged to maintain coordination among the members 
of the team and to keep the members up- to- date and to 
resolve any coordination- related issues.
Data editing
Data editing will be done in two phases: field site editing 
and office- based editing. Field editing will be done by the 
designated member of the surveillance site where they 
will check each questionnaire filled by attending physi-
cian on the hard copy of the questionnaire at the time of 
enrolment. These members will send the questionnaire 
to study RC for quality control and would be responsible 
for reviewing/editing if required at the central office- Aga 
Khan University, Karachi- Pakistan campus.
Data entry and cleaning
Two data entry operators will enter the data into a 
data entry application in parallel. Data entered will be 
compared for entry errors and the identified errors will 
be corrected. The hard copies of surveillance question-
naire will be kept at the secure location until the project 
is being completed.
Plan of analysis and sample size
Data will be analysed using STATA V.11. Descriptive 
data analysis will be performed by calculating frequency 
with percentages for categorical data and mean with SD 
or median with IQRs for continuous scale data. We will 
calculate hospital- based proportions of total iVDPV cases 
in 2- year period. For sensitivity and specificity of the JMF 
signs, we will calculate the receiver operating character-
istics curve by comparing the results based on screening 
with JMF signs with the results of flow cytometry and QIG 
tests. Since this is a surveillance, sample size calculation 
in not obligatory. However, for the sensitivity and speci-
ficity of JMF signs a minimum sample size of 50 PID cases, 
with 5% level of significance, change in sensitivity from 
0.5 to 0.7 using two- sided binomial test and 78% power 
to detect a change in specificity from 0.5 to 0.7 using two- 
sided binomial test.7
Limitations and strategies to overcome
As PID is a rare condition and many children die before 
formal diagnosis, we may not be able to achieve the 
required sample size of 50 PID cases in 2- year duration. 
While the minimum sample size is not a requirement for 
the surveillance objective, it is needed for the calculation 
of sensitivity and specificity of the JMF 10 warning signs. 
To achieve sufficient sample size, the PI of the project 
will review the enrolment data quarterly and may decide 
to expand the sentinel sites to other tertiary care hospi-




The surveillance project has been initiated after the 
formal ethical approval granted by the WHO, Aga Khan 
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University, National Bioethics Committee and Depart-
mental Heads of Paediatrics from each participatory 
hospital.
Informed consent
The formal written consent is taken from the parents or 
guardians of children with PID before the enrolment for 
blood and stool samples. Study details and processes are 
explained in detail, thumb impression is taken instead of 
a signature for parents who would be unable to read and 
write. Furthermore, it is recognised that no additional risk 
is involved as the blood collection for diagnostic testing is 
standard of care, and the stool collection poses no risks.
For HIV testing, we offer pre and post- test counselling 
to the families. If the test comes out positive, a referral will 
be made to the nearest National Aids Control programme 
for free treatment and follow- ups.
Privacy and confidentiality
The information from the participants will be taken by 
maintaining privacy and confidentiality. A unique ID will 
be issued to each participant based on the province and 
hospital so that the names of any participant might not be 
disclosed. For maintaining participant’s confidentiality, 
all data forms, reports, and other records will be identi-
fied by the same unique identifier. All records will be kept 
in a secure location and will be shared only with those 
who will be directly involved in the study such as PI and 
the coordination team members at AKU and WHO. All 
the computerised entries will be done with unique ID’s 
only.
Timeframe
This is a 2- year project to commence after approval of 
Ethical Review Committee (ERC).
Dissemination plan
The scientific paper resulting from this work will be 
submitted for the publication to peer- reviewed journal. 
This is the main study protocol paper which serves to 
inform about the design, methodology and coordina-
tion of the project. Once the surveillance is completed, 
study results will be published as a separate scientific 
paper. Abstracts would be submitted at relevant confer-
ences, if selected will be presented in the form of poster 
or presentation. Study participants will be informed 
about the stool sample results as soon as it is available 
and shared by the NIH. In case of positive results for 
VDPV, parents will be told about further steps. A dissem-
ination seminar will be conducted for the members of 
iVDPV working group, WHO, policymakers, paediatric 
consultants and fellow researchers with same domain 
interest.
Way forward
Pakistan National Registry of Primary Immunodeficiency 
disease will be developed. The aim of the national PID 
registry will be to establish the epidemiological data of 
primary immunodeficiency. Moreover, the registry would 
serve as a database for the coordination cells on PID in 
Pakistan.
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